Table. Time Course of Intravitreal Anti–Vascular Endothelial Growth Factors Reimbursements Between the 2 Weeks Preceding Lockdown Through the First 4 Weeks of Reopening in the Coronavirus Disease 2019 Pandemic.
| Week No. | Patients in 2020, No. | Difference of observed − expected, No. (%) | |
|---|---|---|---|
| Observed | Expected | ||
| Period before lockdown | |||
| Week 10 (March 2-8) | 16 114 | 16 171 | −57 (−0.4) |
| Week 11 (March 9-15) | 17 178 | 17 386 | −208 (−1.2) |
| Total | 33 292 | 33 557 | −265 (−0.8) |
| Female, % | 20 146 (60.5) | 20 372 (60.7) | NA |
| Age, mean (SD), y | 77.3 (11.1) | 77.1 (11.1) | NA |
| New users, No.a | 2993 | 3128 | −135 (−4.3) |
| Lockdown period | |||
| Week 12 (March 16-22) | 14 978 | 17 318 | −2340 (−13.5) |
| Week 13 (March 23-29) | 10 118 | 16 751 | −6633 (−39.6) |
| Week 14 (March 30-April 5) | 8345 | 15 777 | −7432 (−47.1) |
| Week 15 (April 6-12) | 9099 | 17 294 | −8195 (−47.4) |
| Week 16 (April 13-19) | 9018 | 16 355 | −7337 (−44.9) |
| Week 17 (April 20-26) | 11 199 | 16 209 | −5010 (−30.9) |
| Week 18 (April 27-May 3) | 11 199 | 16 209 | −5010 (−30.9) |
| Week 19 (May 4-10) | 13 360 | 17 784 | −4424 (−24.9) |
| Total | 87 316 | 133 697 | −46 381 (−34.7) |
| Female, % | 52 461 (60.1) | 82 069 (61.4) | NA |
| Age, mean (SD), y | 76.8 (11.0) | 77.2 (11.1) | NA |
| New users, No.a | 4343 | 12 512 | −8169 (−65.3) |
| Reopening period | |||
| Week 20 (May 11-17) | 15 188 | 19 435 | −4247 (−21.9) |
| Week 21 (May 18-24) | 15 531 | 18 174 | −2643 (−14.5) |
| Week 22 (May 25-31) | 16 484 | 17 207 | −723 (−4.2) |
| Week 23 (June 1-7) | 15 817 | 16 398 | −581 (−3.5) |
| Total | 63 020 | 71 214 | −8194 (−11.5) |
| Female, % | 38 593 (61.2) | 43 828 (61.5) | NA |
| Age, mean (SD), y | 77.5 (11.0) | 77.3 (11.1) | NA |
| New users, No.a | 4463 | 4692 | −229 (−4.9) |
Abbreviations: NA, not applicable.
a
New use of intravitreal anti–vascular endothelial growth factors was defined by the absence of any such reimbursement during the previous year.